EMA Withdrawn: Trudexa (adalimumab) — Abbott Laboratories Ltd.

View source ↗

Summary

EMA has withdrawn Trudexa (adalimumab) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Psoriatic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• Trudexa (adalimumab)

Snippet

Status: Withdrawn. Therapeutic area: Spondylitis, Ankylosing;Arthritis, Rheumatoid;Arthritis, Psoriatic;Crohn Disease. MAH: Abbott Laboratories Ltd.. Decision date: 29/06/2007